Invasive Bacterial Infections in Children With Sickle Cell Disease: 2014-2019.


Journal

Pediatrics
ISSN: 1098-4275
Titre abrégé: Pediatrics
Pays: United States
ID NLM: 0376422

Informations de publication

Date de publication:
01 Oct 2023
Historique:
accepted: 18 07 2023
pubmed: 28 9 2023
medline: 28 9 2023
entrez: 28 9 2023
Statut: ppublish

Résumé

Children with sickle cell disease (SCD) are at a high risk of invasive bacterial infections (IBI). Universal penicillin prophylaxis and vaccination, especially against Streptococcus pneumoniae, have deeply changed its epidemiology. Analysis of IBI in children with SCD in a post-13-valent pneumococcal vaccine era is limited. Twenty-eight pediatric hospitals from 5 European countries retrospectively collected IBI episodes in SCD children aged 1 month to 18 years between 2014 and 2019. IBI was defined as a positive bacterial culture or polymerase chain reaction from a normally sterile fluid: blood, cerebrospinal, joint, or pleural fluid and deep surgical specimen. We recorded 169 IBI episodes. Salmonella spp. was the main isolated bacteria (n = 44, 26%), followed by Streptococcus pneumonia (Sp; n = 31, 18%) and Staphylococcus aureus (n = 20, 12%). Salmonella prevailed in osteoarticular infections and in primary bacteremia (45% and 23% of episodes, respectively) and Sp in meningitis and acute chest syndrome (88% and 50%, respectively). All Sp IBI occurred in children ≤10 years old, including 35% in children 5 to 10 years old. Twenty-seven (17%) children had complications of infection and 3 died: 2 because of Sp, and 1 because of Salmonella. The main risk factors for a severe IBI were a previous IBI and pneumococcal infection (17 Sp/51 cases). In a post-13-valent pneumococcal vaccine era, Salmonella was the leading cause of bacteremia in IBI in children with SCD in Europe. Sp came second, was isolated in children ≤10 years old, and was more likely to cause severe and fatal cases.

Sections du résumé

BACKGROUND BACKGROUND
Children with sickle cell disease (SCD) are at a high risk of invasive bacterial infections (IBI). Universal penicillin prophylaxis and vaccination, especially against Streptococcus pneumoniae, have deeply changed its epidemiology. Analysis of IBI in children with SCD in a post-13-valent pneumococcal vaccine era is limited.
METHODS METHODS
Twenty-eight pediatric hospitals from 5 European countries retrospectively collected IBI episodes in SCD children aged 1 month to 18 years between 2014 and 2019. IBI was defined as a positive bacterial culture or polymerase chain reaction from a normally sterile fluid: blood, cerebrospinal, joint, or pleural fluid and deep surgical specimen.
RESULTS RESULTS
We recorded 169 IBI episodes. Salmonella spp. was the main isolated bacteria (n = 44, 26%), followed by Streptococcus pneumonia (Sp; n = 31, 18%) and Staphylococcus aureus (n = 20, 12%). Salmonella prevailed in osteoarticular infections and in primary bacteremia (45% and 23% of episodes, respectively) and Sp in meningitis and acute chest syndrome (88% and 50%, respectively). All Sp IBI occurred in children ≤10 years old, including 35% in children 5 to 10 years old. Twenty-seven (17%) children had complications of infection and 3 died: 2 because of Sp, and 1 because of Salmonella. The main risk factors for a severe IBI were a previous IBI and pneumococcal infection (17 Sp/51 cases).
CONCLUSIONS CONCLUSIONS
In a post-13-valent pneumococcal vaccine era, Salmonella was the leading cause of bacteremia in IBI in children with SCD in Europe. Sp came second, was isolated in children ≤10 years old, and was more likely to cause severe and fatal cases.

Identifiants

pubmed: 37767606
pii: 194203
doi: 10.1542/peds.2022-061061
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2023 by the American Academy of Pediatrics.

Auteurs

Jean Gaschignard (J)

Department of Pediatrics, Groupe Hospitalier Nord Essonne, Longjumeau, France.
IAME, INSERM 1137, Hôpital Bichat, Paris, France.

Bérengère Koehl (B)

Departments of Sickle Cell Disease, Hôpital Robert Debré.
Université de Paris-Cité, Paris, France.
INSERM U1134, Integrated Red Globule Biology, Paris, France.

David C Rees (DC)

Red Cell Haematology Laboratory, School of Cancer and Pharmaceutical Sciences, King's College London and King's College Hospital, London, United Kingdom.

Elena Rincón-López (E)

Departments of Pediatrics.
Biomedical Research Networking Center on Infectious Diseases (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain.

Anna Vanderfaeillie (A)

Department of Pediatrics, UMC Saint Pierre, Brussels, Belgium.

Alice Pascault (A)

Departments of Sickle Cell Disease, Hôpital Robert Debré.

Slimane Allali (S)

General Pediatrics and Pediatric Infectious Diseases, Sickle Cell Center, Necker-Enfants Malades Hospital, Université Paris Cité.
Université de Paris-Cité, Paris, France.

Elena Cela (E)

Pediatric Hematology and Oncology Unit, Universidad Complutense de Madrid, Hospital General Universitario Gregorio Marañón, Madrid, Spain.

Marie-Hélène Odièvre (MH)

Pediatrics, Hôpital Trousseau.
Université de Paris-Cité, Paris, France.

Isabelle Hau (I)

Department of Pediatrics, Centre Hospitalier Intercommunal, Créteil, France.

Marisa Oliveira (M)

Pediatric Hematology Unit, Hospital D. Estefânia, Centro Hospitalar Universitário de Lisboa Central, Lisbon, Portugal.

Cécile Guillaumat (C)

Department of Pediatrics, Centre Hospitalier Sud Francilien, Corbeil-Essonne, France.

Valentine Brousse (V)

Departments of Sickle Cell Disease, Hôpital Robert Debré.
Université de Paris-Cité, Paris, France.
INSERM U1134, Integrated Red Globule Biology, Paris, France.

Mariane de Montalembert (M)

General Pediatrics and Pediatric Infectious Diseases, Sickle Cell Center, Necker-Enfants Malades Hospital, Université Paris Cité.
Université de Paris-Cité, Paris, France.

Maria Luisa Navarro Gómez (ML)

Departments of Pediatrics.
Biomedical Research Networking Center on Infectious Diseases (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain.

Naima Beldjoudi (N)

Epidemiology and Clinical Research Department, GH Paris Nord Val de Seine, Assistance Publique - Hôpitaux de Paris, Paris, France.

Eduardo Jesus Bardon-Cancho (EJ)

Pediatric Hematology and Oncology Unit, Universidad Complutense de Madrid, Hospital General Universitario Gregorio Marañón, Madrid, Spain.

Cristina Epalza (C)

Paediatric Infectious Diseases Unit, Department of Paediatrics, Hospital Universitario 12 de Octubre, Madrid, Spain.
Paediatric Research and Clinical Trials Unit (UPIC), Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), Madrid, Spain.
Translational Research Network in Paediatric Infectious Diseases (RITIP), Madrid, Spain.

Classifications MeSH